Clinical Trials Browser

Breast Neoplasms

NCT07340658 2026-04-02

SIE-3

Phase 3 Not yet recruiting

300 enrolled

Breast

Breast Neoplasms

NCT07432178 2026-04-02

CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

Phase 3 Not yet recruiting

2,288 enrolled

Breast

Breast Neoplasms

NCT07502820 2026-03-31

POWER

Phase 3 Not yet recruiting

1,100 enrolled

Breast

Breast Neoplasms

NCT07106632 2026-03-24

OPTIMA-YOUNG

Phase 3 Not yet recruiting

3,380 enrolled

Breast

Breast Neoplasms

NCT07486687 2026-03-20

PLANET

Phase 3 Not yet recruiting

1,000 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07483996 2026-03-19

CRYSTAL

Phase 3 Not yet recruiting

938 enrolled

Breast

Breast Neoplasms

NCT07461454 2026-03-10

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Phase 3 Not yet recruiting

376 enrolled

Breast

Breast Neoplasms

NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Phase 3 Not yet recruiting

400 enrolled

Breast

Breast Neoplasms, Recurrence

NCT07407517 2026-02-12

POLARIS

Phase 3 Not yet recruiting

904 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07385365 2026-02-11

A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer

Phase 3 Not yet recruiting

3,142 enrolled

Breast

Breast Neoplasms

NCT07393321 2026-02-06

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Phase 3 Not yet recruiting

210 enrolled

Breast

Breast Neoplasms

NCT07382687 2026-02-03

Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype

Phase 3 Not yet recruiting

248 enrolled

Breast

Breast Neoplasms

NCT07372144 2026-01-28

IARA

Phase 3 Not yet recruiting

227 enrolled

Breast

Breast Neoplasms

NCT07357298 2026-01-22

Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer

Phase 3 Not yet recruiting

156 enrolled

Breast

Breast Neoplasms

NCT07269691 2025-12-08

RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer

Phase 3 Not yet recruiting

194 enrolled

Breast

Breast Neoplasms

NCT06787118 2025-12-02

PANDORA

Phase 3 Not yet recruiting

130 enrolled

Breast

Breast Neoplasms

NCT07242352 2025-11-21

ADAPTela

Phase 3 Not yet recruiting

1,520 enrolled

Breast

Breast Neoplasms

NCT07213206 2025-10-08

Cinderella

Phase 3 Not yet recruiting

1,500 enrolled

Breast

Breast Neoplasms

NCT07178730 2025-09-17

ADAPT-TN-IV

Phase 3 Not yet recruiting

765 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07084519 2025-07-24

Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction

Phase 3 Not yet recruiting

190 enrolled

Breast

Breast Neoplasms

NCT06835400 2025-07-11

Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

Phase 3 Not yet recruiting

340 enrolled

Breast

Breast Neoplasms

NCT06434077 2025-06-22

Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer

Phase 3 Not yet recruiting

60 enrolled

Breast

Breast Neoplasms

NCT07021261 2025-06-13

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

Phase 3 Not yet recruiting

440 enrolled

Breast

Breast Neoplasms

NCT07005557 2025-06-05

SENIOR

Phase 3 Not yet recruiting

1,244 enrolled

Breast

Breast Neoplasms

NCT06996093 2025-05-30

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Phase 3 Not yet recruiting

2,508 enrolled

Breast

Breast Neoplasms

NCT06223698 2025-04-20

SWE-Switch

Phase 3 Not yet recruiting

3,832 enrolled

Breast

Breast Neoplasms

NCT06929325 2025-04-16

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

Phase 3 Not yet recruiting

312 enrolled

Breast

Breast Neoplasms

NCT06811220 2025-02-06

The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients

Phase 3 Not yet recruiting

140 enrolled

Breast

Breast Neoplasms

NCT06774885 2025-01-14

ROLE OF FOLIC ACID IN THE MANAGEMENT OF ADJUVANT ENDOCRINE THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS

Phase 3 Not yet recruiting

120 enrolled

Breast

Breast Neoplasms, Hot Flashes

NCT06611514 2024-11-19

PROPOSE

Phase 3 Not yet recruiting

95 enrolled

Breast

Breast Neoplasms

NCT06407401 2024-11-05

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer

Phase 3 Not yet recruiting

399 enrolled

Breast

Breast Neoplasms, Musculoskeletal Pain, Drug-Related Side Effects and Adverse Reactions

NCT06561607 2024-08-20

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Phase 3 Not yet recruiting

542 enrolled

Breast

Breast Neoplasms

NCT06270355 2024-02-28

SMART

Phase 3 Not yet recruiting

70,000 enrolled

Breast

Breast Neoplasms

NCT05993559 2024-01-12

Necessity of Post-mastectomy Radiotherapy After Neoadjuvant Chemotherapy and Mastectomy

Phase 3 Not yet recruiting

1,314 enrolled

Breast

Breast Neoplasms

NCT05841381 2023-05-03

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

Phase 3 Not yet recruiting

876 enrolled

Breast

Breast Neoplasms

NCT05253170 2022-03-11

Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients

Phase 3 Not yet recruiting

622 enrolled

Breast

Breast Neoplasms

NCT05172518 2021-12-29

Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer

Phase 3 Not yet recruiting

512 enrolled

Breast

Breast Neoplasms

NCT04973319 2021-07-22

Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

Phase 3 Not yet recruiting

450 enrolled

Breast

Breast Neoplasms

NCT04736589 2021-02-03

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

Phase 3 Not yet recruiting

270 enrolled

Breast

Breast Neoplasms

NCT04337658 2020-04-08

FAVOR

Phase 3 Not yet recruiting

493 enrolled

Breast

Breast Neoplasms

Clinical Trials

Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy

SIE-3

CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

POWER

OPTIMA-YOUNG

PLANET

CRYSTAL

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

POLARIS

A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype

IARA

Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer

RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer

PANDORA

ADAPTela

Cinderella

ADAPT-TN-IV

Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction

Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

SENIOR

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

SWE-Switch

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients

ROLE OF FOLIC ACID IN THE MANAGEMENT OF ADJUVANT ENDOCRINE THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS

PROPOSE

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

SMART

Necessity of Post-mastectomy Radiotherapy After Neoadjuvant Chemotherapy and Mastectomy

Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer

Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients

Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer

Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

FAVOR